Professor Kimiyasu Shiraki of the Department of Virology, University of Toyama School of Medicine was involved in the development of a new therapeutic agent for herpes zoster, Amena Mevir, which was released on September 29, 9 by Maruho Co., Ltd. under the trade name "Amena Leaf Tablets." It has been released as "7mg".
In the first stage of DNA synthesis of herpes virus, the action of an enzyme called helicase primase, which separates double-stranded DNA into single strands and prepares to start DNA synthesis, is essential.The drug is a drug that inhibits this helicase / primase and inhibits the growth of herpesvirus.Therapeutic agents with this new mechanism of action have been attracting attention as next-generation anti-herpes drugs in Japan and overseas, and the two components found by major overseas pharmaceutical companies Bayer and Bellinger in the same way are the next-generation therapeutic agents. I have been a candidate for.
Among them, the University of Toyama clarified the superiority of the action characteristics of amena mevir through joint research with Astellas Pharma, and obtained the world's first approval as Japan's first treatment for herpes zoster on July 29, 7. ..
The drug has high antiviral activity, and it is orally administered once daily to maintain antiviral properties throughout the day. It does not require dose adjustment by renal function. It also has the characteristic of being easy to take.Based on these findings, the drug is evaluated as the most ideal treatment for herpes zoster, and is expected to replace existing anti-herpes drugs and become the standard drug for the treatment of herpes in the world.
